📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
Apollo Hospitals Receives NCLT Order to Convene Meetings for Composite Scheme on May 27, 2026
Apollo Hospitals Enterprise Limited (AHEL) has received an order from the NCLT Chennai regarding its composite scheme of arrangement involving Apollo Healthco, Keimed, and Apollo Healthtech. The tribunal has scheduled the meeting for equity shareholders and unsecured creditors of AHEL for May 27, 2026. Although the company sought to dispense with the secured creditors' meeting citing 90.96% consent, the NCLT has directed that the meeting must proceed on May 27, 2026. This procedural step is crucial for the proposed restructuring of the group's pharmacy and digital health businesses.
Key Highlights
NCLT has fixed May 27, 2026, at 2:30 PM for the meeting of Apollo Hospitals' equity shareholders.
The meeting for unsecured creditors of Apollo Hospitals is scheduled for May 27, 2026, at 11:00 AM.
Tribunal rejected the request to dispense with the secured creditors' meeting despite 90.96% consent already obtained.
Meetings for other involved entities (Transferor Companies) are scheduled for May 26, 2026.
The scheme remains subject to final approvals from shareholders, creditors, and regulatory authorities.
💼 Action for Investors
Investors should track the outcome of the shareholder meeting on May 27, 2026, as this restructuring is a key milestone for the company's long-term strategy. No immediate portfolio action is required until the voting results and subsequent regulatory clearances are finalized.
Loading analysis...
Apollo Pipes Commences Commercial Production at New Mirzapur Plant
Apollo Pipes Limited has officially commenced commercial production at its new manufacturing facility in Mirzapur, Uttar Pradesh, as of April 14, 2026. This strategic expansion, located near Varanasi, follows a series of planned developments first disclosed in May 2024. The plant is expected to significantly enhance the company's production capacity and market penetration in Northern India. This milestone marks the completion of a multi-year investment cycle aimed at scaling the company's piping and plumbing business.
Key Highlights
Commencement of commercial operations at the Mirzapur plant effective April 14, 2026.
Project execution follows a timeline of regulatory disclosures dating back to May 20, 2024.
Strategic location near Varanasi to optimize distribution and logistics in the Uttar Pradesh region.
The expansion is intended to cater to rising demand in the building materials and infrastructure sectors.
💼 Action for Investors
Investors should monitor the plant's capacity utilization rates and its impact on volume growth in the upcoming quarterly financial results. The expansion strengthens the company's competitive position in the regional market.
Loading analysis...
Apollo Hospitals Acquires Remaining Stake in AHLL for Rs 18.69 Cr; Becomes 100% Subsidiary
Apollo Hospitals Enterprise Limited has completed the acquisition of the remaining stake in its subsidiary, Apollo Health and Lifestyle Limited (AHLL). The company purchased 775,744 equity shares from individual shareholders at a price of Rs 241 per share, amounting to a total consideration of Rs 18.69 crores. This transaction follows previous acquisitions from IFC and IFC EAF, which had already increased the stake to 99.42%. With this final purchase, AHLL has now become a 100% wholly-owned subsidiary of Apollo Hospitals.
Key Highlights
Acquired 775,744 equity shares of Apollo Health and Lifestyle Limited (AHLL) from individual shareholders.
The acquisition was executed at a price of Rs 241 per share, totaling Rs 18.69 crores.
Company's shareholding in AHLL increased from 99.42% to 100% following this transaction.
AHLL is now a wholly-owned subsidiary, simplifying the corporate structure for the retail healthcare business.
💼 Action for Investors
Investors should view this as a positive consolidation move that gives Apollo Hospitals full control over its primary care and diagnostic business. No immediate action is required, but it reinforces the company's focus on its retail health growth engine.
Loading analysis...
Apollo Hospitals Receives NCLT Order for Composite Scheme of Arrangement
Apollo Hospitals Enterprise Limited (AHEL) has received a certified order from the NCLT Chennai Bench regarding its composite scheme of arrangement. The scheme involves the restructuring of Apollo Healthco, Keimed Private Limited, and Apollo Healthtech to streamline the pharmacy distribution and digital health business. The Tribunal has directed AHEL to convene meetings of its equity shareholders and creditors to seek approval for the proposed arrangement. This is a critical step in the company's long-term strategy to consolidate its pharmacy supply chain and digital platform.
Key Highlights
NCLT order dated March 26, 2026, received by the company on April 9, 2026, regarding the composite scheme.
The arrangement involves Apollo Hospitals (Demerged Co), Apollo Healthco (Transferor 1), Keimed (Transferor 2), and Apollo Healthtech (Resultant Co).
Tribunal directed the convening of a meeting for AHEL equity shareholders via VC/OAVM to vote on the scheme.
Meetings for equity shareholders of Keimed Private Limited and Apollo Healthtech Limited have been dispensed with by the Tribunal.
The restructuring aims to integrate the wholesale distribution business of Keimed with the pharmacy platform of Apollo Healthco.
💼 Action for Investors
Investors should vote in favor of the scheme as it is expected to simplify the corporate structure and unlock value in the pharmacy and digital health segments. Monitor the upcoming shareholder meeting date and subsequent voting results for further clarity on the execution timeline.
Loading analysis...
Apollo Micro Systems Completes Blast Trials for Limpet Mines; Sole Indian Developer for Navy
Apollo Micro Systems has successfully completed blast trials for Limpet Mines, which are specialized diver-carried mines used in naval defense. The company is currently the only Indian firm to have successfully developed this product for the Indian Navy, creating a significant competitive moat. This milestone allows the company to offer a complete spectrum of underwater mines, ranging from shallow to deep-water categories. This development significantly strengthens the company's portfolio in the niche underwater Electronic Warfare systems segment.
Key Highlights
Successfully completed blast trials for Limpet Mines used in Naval Defence.
Recognized as the only Indian company to develop this specific product for the Indian Navy.
Expands product range to cover the complete spectrum of underwater mines (Shallow, Deep, and Limpet).
Strengthens the company's technological positioning in underwater Electronic Warfare systems.
💼 Action for Investors
Investors should view this as a major R&D milestone that positions the company for exclusive defense contracts. Monitor for upcoming order book additions specifically related to naval underwater systems.
Loading analysis...
Apollo Hospitals Gets NCLT Approval to Convene Meetings for Composite Scheme of Arrangement
Apollo Hospitals Enterprise Limited (APOLLOHOSP) has received an order from the NCLT Chennai Bench regarding its composite scheme of arrangement involving Apollo Healthco, Keimed, and Apollo Healthtech. The Tribunal has directed the company to convene meetings for its equity shareholders, secured creditors, and unsecured creditors to seek approval for the restructuring. As of June 2025, the company reported a paid-up share capital of ₹71.89 crore consisting of 14.37 crore equity shares. This regulatory milestone is a key step in the company's plan to consolidate its pharmacy distribution and digital health platforms.
Key Highlights
NCLT Chennai Bench allowed the application for the composite scheme of arrangement in an order dated March 26, 2026.
The Tribunal directed the convening of meetings for equity shareholders and creditors of Apollo Hospitals to vote on the scheme.
Meetings for shareholders of Apollo Healthco, Keimed, and Apollo Healthtech have been dispensed with by the Tribunal.
The scheme involves the demerger and consolidation of health-tech and pharmacy distribution assets into a resultant company.
Final implementation is subject to the approval of shareholders, creditors, and a final sanction order from the NCLT.
💼 Action for Investors
Investors should monitor the outcomes of the upcoming shareholder and creditor meetings as this restructuring is intended to unlock value in the digital health segment. No immediate action is required, but the progress indicates the consolidation plan is on track.
Loading analysis...
Apollo Pipes Postpones Mirzapur Plant Commercial Production to Late April 2026
Apollo Pipes Limited has announced a further delay in the commencement of commercial operations at its new manufacturing facility in Mirzapur, Uttar Pradesh. The company now targets the end of April 2026 for production to begin, contingent upon achieving operational readiness. This announcement follows a series of previous timeline updates dating back to May 2024 and May 2025. Repeated delays in capacity expansion typically defer projected revenue growth and may impact the company's ability to capture market share in the North Indian region as originally planned.
Key Highlights
Commercial production at the Mirzapur (Varanasi) plant is now expected by the end of April 2026.
The project has undergone multiple timeline revisions with previous disclosures in May 2024, May 2025, and January 2026.
Commencement remains subject to final operational readiness at the Uttar Pradesh facility.
The delay impacts the company's strategic expansion plans for the high-demand North Indian market.
💼 Action for Investors
Investors should monitor management's commentary in the upcoming quarterly earnings call to understand the specific bottlenecks causing recurring delays. The stock may face short-term pressure as growth triggers from the new capacity are pushed further into the future.
Loading analysis...
Apollo Hospitals Completes 30.58% Stake Buy in AHLL for Rs 12,540.68 Million
Apollo Hospitals Enterprise Limited has successfully completed the acquisition of a 30.58% equity stake in its subsidiary, Apollo Health and Lifestyle Limited (AHLL). The stake was acquired from International Finance Corporation (IFC) and IFC EAF for a total consideration of Rs 12,540.68 million. Following this transaction, Apollo Hospitals' effective shareholding in AHLL has increased significantly to 99.42%. This move consolidates the company's control over its retail healthcare and primary care business segments.
Key Highlights
Acquisition of 41,650,638 equity shares representing a 30.58% stake in AHLL.
Total purchase consideration of Rs 12,540.68 million paid to IFC and IFC EAF.
Effective shareholding in the subsidiary AHLL increased to 99.42%.
Transaction completed following necessary approval from the Competition Commission of India (CCI).
Consolidates ownership in the retail healthcare vertical including clinics and diagnostics.
💼 Action for Investors
This consolidation of ownership in a key growth subsidiary is a positive long-term move; investors should monitor AHLL's contribution to the consolidated bottom line. The stock may see positive sentiment as the company simplifies its corporate structure and gains full control over AHLL's cash flows.
Loading analysis...
Apollo Micro Systems to List 28.89 Lakh Equity Shares from March 19
Apollo Micro Systems has received trading approval for 28,89,044 equity shares issued on a preferential basis to non-promoters. These shares were issued at a price of Rs. 114 per share, including a premium of Rs. 113, following the conversion of warrants. The shares will be admitted for trading on both NSE and BSE starting March 19, 2026. These new shares are subject to a mandatory lock-in period until September 19, 2026.
Key Highlights
Listing of 28,89,044 equity shares with a face value of Re. 1 each
Shares issued at a total price of Rs. 114 per share (Rs. 113 premium)
Allotment resulted from the conversion of warrants previously issued to non-promoters
Trading commences on NSE and BSE effective from March 19, 2026
Specific lock-in period for these shares is valid until September 19, 2026
💼 Action for Investors
Investors should monitor the slight equity dilution resulting from this conversion. No immediate action is required as this is a procedural listing of previously announced preferential allotments.
Loading analysis...
Apollo Micro Systems Receives Trading Approval for 28.89 Lakh Equity Shares
Apollo Micro Systems has received trading approval from NSE and BSE for 28,89,044 equity shares of Re. 1/- each. These shares were issued to non-promoters on a preferential basis following the conversion of warrants. The shares were issued at a price of Rs. 114 per share, including a premium of Rs. 113. Trading for these new securities is scheduled to commence on March 19, 2026, with a lock-in period ending on September 19, 2026.
Key Highlights
Approval for listing and trading of 28,89,044 equity shares on NSE and BSE.
Shares issued at Rs. 114 per share (Face Value Re. 1 + Premium Rs. 113).
Issued to non-promoters pursuant to the conversion of warrants.
Trading effective from March 19, 2026, with a lock-in period until September 19, 2026.
Total distinctive numbers for the new shares range from 354391701 to 357280744.
💼 Action for Investors
Investors should monitor the slight equity dilution following this warrant conversion. The conversion at Rs. 114 per share reflects institutional or high-net-worth individual interest at that valuation level.
Loading analysis...
Gujarat Apollo Targets ₹300 Cr Revenue in 3 Years via Dual-Engine Growth Strategy
Gujarat Apollo Industries has unveiled a strategic roadmap to achieve over ₹300 crore in combined revenue within the next three fiscal cycles. The company is leveraging its legacy in road-construction and mining equipment (target ₹210 Cr) while diversifying into the high-demand agriculture sector (target ₹90 Cr). A committed capex of ₹26 crore, funded through equity warrant conversion, will be used for facility modernization and capacity expansion by June 2026. This strategy marks the company's return to the road-construction segment following the end of a non-compete agreement.
Key Highlights
Targeting ₹300 Cr+ combined revenue in 3 years and ₹500 Cr+ by 2031
Allocating ₹26 Cr for modernization and expansion, funded via preferential warrant conversion
Expanding into Agri-equipment with a ₹90 Cr revenue target through subsidiaries like Fieldtrack and Ganesh Agro
Restarting the Road-construction equipment business and developing new Pick & Carry cranes
Acquiring a 50% stake in Ganesh Agro Equipment to bolster the agriculture portfolio
💼 Action for Investors
Investors should monitor the execution of the ₹26 crore capex and the successful re-entry into the road-construction market. The diversification into agri-equipment offers a balanced risk profile, making the company a potential turnaround play in the industrial sector.
Loading analysis...
Apollo Pipes Appoints Parag Dadeech as Chief Operating Officer
Apollo Pipes has appointed Mr. Parag Dadeech as the Chief Operating Officer (COO) effective March 02, 2026. Mr. Dadeech is a seasoned professional with over 28 years of global experience in the manufacturing sector, specializing in operations and supply chain management. His academic credentials include a Master's in Chemical Engineering from the University of Tennessee and a certification from IIM Kolkata. This appointment is expected to strengthen the company's operational efficiency and strategic manufacturing initiatives.
Key Highlights
Appointment of Mr. Parag Dadeech as COO and Senior Management Personnel effective March 02, 2026
Brings over 28 years of global experience in manufacturing, operations, and international business
Holds a Master's degree in Chemical Engineering from the University of Tennessee and is a Lean Six Sigma Master Black Belt
Expertise includes Business Excellence, Global Supply Chain, and Capital Projects management
💼 Action for Investors
Investors should view this as a positive step toward professionalizing management and improving operational scale. Monitor future quarterly results for improvements in manufacturing margins and supply chain efficiencies under the new leadership.
Loading analysis...
Apollo Pipes Increases Stake in Subsidiary Kisan Mouldings to 61.94% for Rs 9.8 Cr
Apollo Pipes Limited has increased its ownership in its subsidiary, Kisan Mouldings Limited (KML), by acquiring an additional 3.34% stake through a secondary purchase. The transaction, valued at approximately Rs 9.8 Crores, raises Apollo's total holding from 58.60% to 61.94%. KML is a key player in the PVC pipes and fittings industry, reporting a turnover of Rs 273.35 Crores for FY25. This strategic investment demonstrates Apollo Pipes' commitment to consolidating its position within its core business segment.
Key Highlights
Acquired an additional 3.34% equity stake in Kisan Mouldings Limited (KML) via secondary purchase
Total shareholding in the subsidiary increased from 58.60% to 61.94%
The acquisition was completed for a cash consideration of approximately Rs 9.8 Crores
Target entity KML reported a steady turnover of Rs 273.35 Crores in FY 2024-25
The move is classified as a strategic investment in the PVC Pipes & Fittings industry
💼 Action for Investors
Investors should view this as a positive move to consolidate control over a significant subsidiary. Monitor how this increased ownership impacts consolidated earnings and operational synergies in the coming quarters.
Loading analysis...
Promoter Group Entity Acquires 1.18% Stake in Apollo Pipes for ₹76.65 Crore
S Gupta Holding Private Limited, a member of the promoter group, has acquired 5,25,000 equity shares of Apollo Pipes through a market purchase. The transaction, valued at approximately ₹76.65 crore, represents a 1.18% stake in the company. This significant acquisition by the promoter group is a strong signal of confidence in the company's valuation and future prospects. The trade was executed on February 13, 2026, and reported to the exchanges on February 19.
Key Highlights
Acquisition of 5,25,000 equity shares by promoter group entity S Gupta Holding Private Limited.
Total transaction value of ₹76.65 crore executed via market purchase.
The purchase represents a 1.18% stake in the company, increasing the entity's holding from nil to 1.18%.
Transaction executed at an approximate price of ₹1,460 per share on February 13, 2026.
💼 Action for Investors
Promoter buying at market prices is typically a bullish sign for long-term investors. Consider this a positive reinforcement of the company's fundamentals and monitor for further insider activity.
Loading analysis...
Gujarat Apollo Q3 Consolidated PAT Plummets 90% YoY to ₹22 Lakhs; Equity Capital Increases
Gujarat Apollo Industries reported a significant decline in consolidated profitability for the quarter ended December 31, 2025, with PAT dropping to ₹22.04 lakhs from ₹228.75 lakhs in the previous year. While consolidated revenue saw a modest 9% growth to ₹1,187.45 lakhs, standalone revenue fell by 33.8% to ₹920.99 lakhs. The company expanded its equity base by allotting 11.70 lakh shares following warrant conversions, which will lead to equity dilution. Despite the profit slump, the company maintains a strong balance sheet with zero debt and no loan defaults.
Key Highlights
Consolidated Net Profit fell 90.3% YoY to ₹22.04 lakhs in Q3 FY26 compared to ₹228.75 lakhs in Q3 FY25.
Consolidated Revenue from Operations grew 9% YoY to ₹1,187.45 lakhs from ₹1,088.87 lakhs.
Standalone Revenue from Operations declined 33.8% YoY to ₹920.99 lakhs.
Equity Share Capital increased from ₹11.80 crore to ₹12.97 crore due to the conversion of 11.70 lakh warrants.
The company remains debt-free with zero financial indebtedness reported as of December 31, 2025.
💼 Action for Investors
Investors should exercise caution as the sharp drop in consolidated margins and net profit indicates operational pressures. The recent equity dilution from warrant conversions further impacts EPS, making the valuation less attractive until profitability recovers.
Loading analysis...
Apollo Micro Systems Q3 Revenue Surges 70% to ₹252 Cr; Order Book Hits ₹1,305 Cr
Apollo Micro Systems reported its highest-ever quarterly performance with revenue surging 70% YoY to ₹252 crores and 9-month PAT climbing 67% to ₹71 crores. The company maintains a robust consolidated order book of ₹1,305 crores and has provided an aggressive organic growth guidance of 45-50% CAGR for the next three years. Strategically, the firm is transitioning from a subsystem provider to a full-fledged weapon system manufacturer, supported by significant R&D and capacity expansion plans. Management is also actively pursuing acquisitions, with 1-2 deals expected to close before the end of the current financial year.
Key Highlights
Q3 FY26 revenue increased by 70% YoY to ₹252 crores, while 9M FY26 PAT rose 67% to ₹71 crores.
Consolidated order book stands at ₹1,305 crores as of December 31, 2025.
Management projects a 45-50% organic revenue CAGR over the next three years, excluding acquisitions.
Allocated ₹50-60 crores for near-term R&D and ₹100-150 crores for a new 5-acre facility expansion.
Active due diligence underway for three potential acquisitions to enhance technological capabilities.
💼 Action for Investors
Investors should focus on the company's transition into high-value weapon systems and the execution of its ₹1,305 crore order book. The aggressive 45-50% growth guidance and upcoming acquisitions suggest strong momentum, though capital allocation for massive expansions warrants monitoring.
Loading analysis...
Apollo Micro Systems H1 FY26 PAT Surges 97% to ₹48 Cr; Guides 45-50% CAGR
Apollo Micro Systems reported a robust H1 FY26 with revenue growing 42% semi-annually to ₹359 crores and PAT nearly doubling to ₹48 crores. The company completed the ₹107 crore acquisition of Ideal Explosives Limited, marking a strategic entry into high-energy explosives and weapon filling lines. Management has provided a strong growth guidance of 45-50% CAGR for FY26 and FY27, excluding the impact of the new acquisition. Expansion at Unit 3 is progressing well, with full-fledged production expected by Q1 FY27, potentially increasing capacity by eight times.
Key Highlights
H1 FY26 Revenue grew 42% semi-annually to ₹359 crores with EBITDA margins expanding 600 bps to 28%.
Profit After Tax (PAT) for H1 FY26 rose 97% semi-annually to ₹48 crores.
Completed 100% acquisition of Ideal Explosives Limited for ₹107 crores for backward and forward integration.
Unit 3 Phase 1 partial production has commenced, with an 8x capacity increase expected upon full completion.
Management maintains a revenue growth guidance of 45-50% CAGR for the core business over the next two years.
💼 Action for Investors
Investors should focus on the successful integration of Ideal Explosives and the timely operationalization of Unit 3, which are critical for meeting the high growth guidance. The company's transition from a subsystem provider to a full-fledged weapons manufacturer enhances its long-term valuation in the defense sector.
Loading analysis...
Apollo Hospitals Q3 FY26: Consolidated PAT Surges 170% YoY to ₹5,023 Million
Apollo Hospitals Enterprise Limited reported a robust performance for Q3 FY26, with consolidated revenue growing 17% YoY to ₹64,774 million. The company's bottom line saw a massive jump, with PAT increasing 170% YoY to ₹5,023 million, driven by strong operational performance across all business verticals. The core Healthcare Services segment maintained healthy EBITDA margins of 24.8%, while the Apollo HealthCo and AHLL segments both recorded 20% revenue growth, signaling strong momentum in digital health and retail clinics.
Key Highlights
Consolidated Revenue increased by 17% YoY to ₹64,774 million in Q3 FY26.
Consolidated PAT witnessed a significant 170% YoY surge, reaching ₹5,023 million.
Healthcare Services (Hospitals) reported an EBITDA margin of 24.8% with 67% occupancy.
Apollo HealthCo (Digital & Pharmacy) revenue grew 20% YoY to ₹28,274 million with 7,113 outlets.
Retail Health (AHLL) EBITDA grew by 39% YoY to ₹476 million, reflecting improved profitability.
💼 Action for Investors
Investors should take note of the significant margin expansion and the massive jump in PAT, which indicates strong operational efficiency. The continued growth in the digital health platform (Apollo 24|7) and the pharmacy network strengthens the company's long-term competitive position.
Loading analysis...
Apollo Hospitals Q3 FY26 PAT Surges 170% YoY to ₹4,219 Million
Apollo Hospitals reported a robust performance for Q3 FY26, with consolidated revenue growing 17% YoY to ₹64,774 million. The company's Profit After Tax (PAT) saw a massive jump of 170% YoY, reaching ₹4,219 million, driven by strong operational efficiencies and growth across all business segments. Healthcare services remained the primary contributor with a 24.8% EBITDA margin, while the digital health and pharmacy segment (HealthCo) continued its growth trajectory with 20% revenue growth.
Key Highlights
Consolidated PAT increased by 170% YoY to ₹4,219 million in Q3 FY26.
Healthcare Services revenue grew 14% YoY to ₹31,832 million with an EBITDA margin of 24.8%.
Average Revenue per IP Patient (ARPOB) stood at ₹180,917 with 67% occupancy across 10,325 beds.
Apollo HealthCo (Digital & Pharmacy) revenue rose 20% YoY to ₹28,274 million.
Retail Health (AHLL) EBITDA grew by 39% YoY to ₹476 million, showing improved profitability in diagnostics and clinics.
💼 Action for Investors
The strong growth in PAT and steady margins in the core hospital business make this a positive update for long-term investors. Monitor the continued scaling and path to profitability of the Apollo 24|7 digital platform as it integrates further with the pharmacy business.
Loading analysis...
Apollo Hospitals Q3 FY26: PAT Surges 170% YoY to ₹5,023 Million; HealthCo Turns Profitable
Apollo Hospitals Enterprise Limited reported a robust Q3 FY26 with consolidated revenue growing 15% YoY to ₹64,774 million. The company achieved a significant milestone as its Apollo HealthCo segment (Digital & Pharmacy) turned EBITDA positive at ₹1,279 million, compared to a loss of ₹1,027 million in the previous year. Net profit (PAT) saw a massive 170% jump to ₹5,023 million, driven by strong hospital margins and the digital turnaround. The core Healthcare Services division maintained a healthy 24.8% EBITDA margin with an average revenue per inpatient of ₹180,917.
Key Highlights
Consolidated Revenue increased 15% YoY to ₹64,774 million in Q3 FY26.
Net Profit (PAT) grew by 170% YoY to ₹5,023 million.
Apollo HealthCo achieved EBITDA of ₹1,279 million, a sharp recovery from a ₹1,027 million loss in Q3 FY25.
Healthcare Services (Hospitals) reported 14% revenue growth and 18% EBITDA growth with 67% occupancy.
Pharmacy network expanded to 7,113 outlets with 46 million registered users on the Apollo 24|7 platform.
💼 Action for Investors
The turnaround in the digital health and pharmacy segment is a major positive trigger for the stock's valuation. Investors should maintain a positive outlook given the strong hospital margins and the scaling of the omni-channel healthcare platform.